CanSino vaccine for Covid-19 looking promising after phase 2 human trials
CanSino’s experimental vaccine has completed the second of three stages of human testing required before a medicine can be sold
20 July 2020 - 17:04
Paris — CanSino Biologics’ experimental coronavirus vaccine showed promising results in a mid-stage clinical study, paving the way for the next phase of tests as it jostles with Western pharma giants to deliver one of the first pandemic vaccines.
The shot was shown to be safe and induced an immune response, according to a study released in the medical journal The Lancet. Still, the authors stressed that no participants were exposed to SARS-CoV-2 virus after vaccination, so it wasn’t possible for this study to determine whether the candidate effectively protects against infection...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.